NAUT Valuation

Nautilus Biotechnology Inc

Add to Watchlist

Advanced Chart

0.758

-0.003(-0.394%)1D

Overview
Forecast
Valuation
Earnings

NAUT Relative Valuation

NAUT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAUT is overvalued; if below, it's undervalued.

Historical Valuation

Nautilus Biotechnology Inc (NAUT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 384.00 is considered Overvalued compared with the five-year average of -6.51. The fair price of Nautilus Biotechnology Inc (NAUT) is between 0.20 to 0.61 according to relative valuation methord. Compared to the current price of 0.76 USD , Nautilus Biotechnology Inc is Overvalued By 24.48%.

Relative Value

Fair Zone

0.20-0.61

Current Price：0.76

24.48%

Overvalued

-1.32

Trailing

Forward

0.19

EV/EBITDA

Nautilus Biotechnology Inc. (NAUT) has a current EV/EBITDA of 0.19. The 5-year average EV/EBITDA is -2.62. The thresholds are as follows: Strongly Undervalued below -10.51, Undervalued between -10.51 and -6.57, Fairly Valued between 1.33 and -6.57, Overvalued between 1.33 and 5.27, and Strongly Overvalued above 5.27. The current Forward EV/EBITDA of 0.19 falls within the Historic Trend Line -Fairly Valued range.

0.17

EV/EBIT

Nautilus Biotechnology Inc. (NAUT) has a current EV/EBIT of 0.17. The 5-year average EV/EBIT is -2.48. The thresholds are as follows: Strongly Undervalued below -10.31, Undervalued between -10.31 and -6.40, Fairly Valued between 1.44 and -6.40, Overvalued between 1.44 and 5.35, and Strongly Overvalued above 5.35. The current Forward EV/EBIT of 0.17 falls within the Historic Trend Line -Fairly Valued range.

384.00

Nautilus Biotechnology Inc. (NAUT) has a current PS of 384.00. The 5-year average PS is 534.28. The thresholds are as follows: Strongly Undervalued below -1748.02, Undervalued between -1748.02 and -606.87, Fairly Valued between 1675.43 and -606.87, Overvalued between 1675.43 and 2816.57, and Strongly Overvalued above 2816.57. The current Forward PS of 384.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Nautilus Biotechnology Inc. (NAUT) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.41. The thresholds are as follows: Strongly Undervalued below -12.78, Undervalued between -12.78 and -8.09, Fairly Valued between 1.27 and -8.09, Overvalued between 1.27 and 5.96, and Strongly Overvalued above 5.96. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Nautilus Biotechnology Inc. (NAUT) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.25. The thresholds are as follows: Strongly Undervalued below -12.12, Undervalued between -12.12 and -7.69, Fairly Valued between 1.18 and -7.69, Overvalued between 1.18 and 5.62, and Strongly Overvalued above 5.62. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Nautilus Biotechnology Inc (NAUT) has a current Price-to-Book (P/B) ratio of 0.49. Compared to its 3-year average P/B ratio of 1.08 , the current P/B ratio is approximately -54.48% higher. Relative to its 5-year average P/B ratio of 0.33, the current P/B ratio is about 50.80% higher. Nautilus Biotechnology Inc (NAUT) has a Forward Free Cash Flow (FCF) yield of approximately -61.74%. Compared to its 3-year average FCF yield of -23.00%, the current FCF yield is approximately 168.46% lower. Relative to its 5-year average FCF yield of -18.49% , the current FCF yield is about 233.95% lower.

0.49

P/B

Median3y

1.08

Median5y

0.33

-61.74

FCF Yield

Median3y

-23.00

Median5y

-18.49

Competitors Valuation Multiple

The average P/S ratio for NAUT's competitors is 73.09, providing a benchmark for relative valuation. Nautilus Biotechnology Inc Corp (NAUT) exhibits a P/S ratio of 384.00, which is 425.39% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NAUT.O

Nautilus Biotechnology Inc

Pliant Therapeutics Inc

53.68

96.38M

NTHI.O

NeOnc Technologies Holdings Inc

Performance Decomposition

Market capitalization of NAUT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NAUT in the past 1 year is driven by Unknown.